2024-12-12 - Analysis Report
## Merck & Co Inc (MRK) Stock Review

**1. Performance Relative to S&P 500 (VOO):**

Merck & Co Inc (MRK) is a leading pharmaceutical company.  The cumulative return of MRK over the measured period is 65.96%, while the S&P 500 (VOO) returned 120.40%.  Therefore, MRK underperformed VOO by 54.4 percentage points.  The relative underperformance places MRK in the 8.3rd percentile of its historical range of under/outperformance relative to the S&P 500.  This indicates that MRK's current underperformance is relatively mild compared to its historical fluctuations against the S&P 500.  The provided alpha consistently shows negative values (-0.1), suggesting that MRK's returns have lagged the market benchmark after adjusting for risk (beta).  Beta values fluctuate, indicating variability in the stock's price movements relative to the overall market.

**2. Recent Price Movement:**

* **Closing Price:** $101.0 (Last market: $99.84)
* **5-day Moving Average:** $102.56
* **20-day Moving Average:** $100.2065
* **60-day Moving Average:** $105.9962

The stock price is currently below its 5-day and 60-day moving averages, suggesting a short-term downtrend, but above its 20-day moving average indicating potential short-term support.  The difference between the closing price and the last market price ($101.0 vs $99.84) indicates a slight upward movement.  However, without further context about the market timing this should be taken only as a general trend.

**3. Technical Indicators and Expected Return:**

* **RSI:** 62.19 –  Suggests the stock is neither overbought nor oversold, although approaching the upper limit of the neutral range.
* **PPO:** 0.58 – A positive value indicates upward momentum.
* **20-day Relative Divergence:** -0.9 – Shows a recent short-term downward trend.
* **Expected Return:** 0.0% – This indicates that the model projects no significant outperformance of the S&P 500 over the long term (2+ years) for a buy-and-hold strategy. Given the historical underperformance compared to the S&P 500, this is consistent.


**4. Recent Earnings Analysis:**

The provided earnings data shows some volatility in both EPS and Revenue. There is no clear trend of consistent growth.

* **EPS:** Fluctuates significantly between quarters, with a high of $2.15 in Q2 2024 and a low of $1.25 in Q3 2024.
* **Revenue:** Shows a general upward trend, but with some quarterly variations.  There's no clear acceleration or deceleration of growth.
* **Notable Beats/Misses:**  No information on expectations is given so any beats or misses cannot be evaluated.

**5. Financial Information Analysis:**

* **Revenue:**  Generally increasing, although there is some fluctuation.
* **Profit Margin:**  Generally high and consistent, with minor fluctuations quarter to quarter.
* **Equity:** Shows growth, with some quarter-to-quarter variations.
* **ROE:** Highly volatile, ranging from a significant negative value (-3.26% in Q4 2023) to a strong positive value (12.52% in Q2 2024). This variability warrants further investigation.


**6. News and Recent Issues:**

No news or recent market outlook, analyst opinions or performance highlights were provided.  Information on recent earnings announcements is present in section 4, but requires context of market expectations for a complete analysis.

**7. Overall Analysis:**

MRK has underperformed the S&P 500 (VOO) over the given period.  While the recent price action shows some short-term instability, technical indicators are not overly bullish or bearish.  Earnings show some volatility, but generally positive revenue growth.  The significant fluctuations in ROE require further analysis.  The lack of current news and analyst sentiment prevents a more thorough evaluation.  The projected 0% long-term outperformance versus the S&P 500 suggests a cautious approach to investment. More comprehensive data, including market expectations for earnings, and external factors affecting the pharmaceutical industry, would be necessary for a complete assessment.

**8. Disclaimer:** This analysis is based solely on the provided data and should not be considered financial advice.  Investing in the stock market involves risk, and past performance does not guarantee future results.  Consult with a qualified financial advisor before making any investment decisions.
